Journal of the American College of Radiology
Volume 5, Issue 1 , Pages 53-56, January 2008

Impact on Hospital Policy: Yale Experience

  • Jeffrey C. Weinreb, MD

      Affiliations

    • Corresponding Author InformationCorresponding author and reprints: Jeffrey C. Weinreb, MD, Yale School of Medicine, 333 Cedar St, MRC 147, New Haven, CT 06520-8042

Yale School of Medicine, New Haven, Connecticut.

To limit patients who may be at risk for nephrogenic systemic fibrosis from exposure to gadolinium-based magnetic resonance contrast agents, new policies and procedures have been implemented at Yale-New Haven Hospital. These changes include screening patients for low estimated glomerular filtration rates and risk factors for chronic kidney disease, giving increased attention to the types and doses of contrast agent administered, agreement on alternative imaging algorithms, and education at all levels of the medical community. The rationale for these changes is discussed.

Key Words: Nephrogenic systemic fibrosis, nephrogenic fibrosing dermopathy, MRI contrast, MRI safety, hospital policy, kidney disease

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1546-1440(07)00447-4

doi:10.1016/j.jacr.2007.08.012

Journal of the American College of Radiology
Volume 5, Issue 1 , Pages 53-56, January 2008